Hyperactivation of transforming growth factor-β (TGF-β) signaling pathway is a common feature of hepatocellular carcinoma (HCC) progression. However, the driver factors leading to enhanced TGF-β activity are not well characterized. Here, we explore the mechanisms that loss of Krüppel-like factor 4 (KLF4) exacerbates oncogenic TGF-β signaling in human HCC. The expression of KLF4 and TGF-β signaling components in primary HCC and their clinicopathologic relevance and significance was evaluated by using tissue microarray and immunohistochemistry. Cellular and molecular impacts of altered KLF4 expression and TGF-β signaling were determined using immunofluorescence, western blot, reverse-transcriptase PCR, chromatin immunoprecipitation and promoter reporter assays. Loss of KLF4 expression in primary HCC closely correlated with decreased Smad7 expression, increased p-Smad2/3 expression and independently predicts reduced overall and relapse-free survival after surgery. TGF-β signaling components were expressed in most HCC cells, and activation of TGF-β signaling promoted cell migration and invasion. Enforced KLF4 expression blocked TGF-β signal transduction and inhibited cell migration and invasion via activation of Smad7 transcription, whereas deletion of its C-terminal zinc-finger domain diminished this effect. KLF4 protein physically interacts with the Smad7 promoter. Promoter deletion and point mutation analyses revealed that a region between nucleotides -15 bp and -9 bp of the Smad7 promoter was required for the induction of Smad7 promoter activity by KLF4. Our data indicate that KLF4 suppresses oncogenic TGF-β signaling by activation of Smad7 transcription, and that loss of KLF4 expression in primary HCC may contribute to activation of oncogenic TGF-β signaling and subsequent tumor progression.
INTRODUCTION
Hepatocellular carcinoma (HCC) is one of the most common malignancies worldwide, with an estimated over half a million new cases and an almost equal number of deaths each year. 1 Surgical treatment remains the mainstay of curative therapy for patients with HCC. However, despite treatment with curative intent, later recurrence and/or metastatic spread are common and negatively affect survival. The overall prognosis is still unsatisfactory, and little progress has been made in finding new treatment options. As such, it is urgent to elucidate the molecular pathogenesis and identify molecular targets responsible for the biological behavior of HCC so that effective therapy for this fatal disease can be developed.
The transforming growth factor-β (TGF-β) signaling pathway, which contributes to liver fibrosis, cirrhosis and subsequent progression to HCC, has a central role in hepatocarcinogenesis. 2, 3 In response to TGF-β, receptor-activated Smads are phosphorylated in their C-terminal SXS motif by type I receptors. Phosphorylated receptor-activated Smads form a complex with Smad4 and are transported into the nucleus where they regulate target genes. TGF-β signaling is tightly controlled by many factors, including Smad7, which is the principal negative feedback regulator. 4 Smad7 represses TGF-β signaling by stably binding to the cytoplasmic domain of activated type I receptors and blocking Smad2/3 phosphorylation. 4 It was initially thought that TGF-β exerted tumor suppressive functions at early stages of HCC because it triggers senescence and growth inhibition in some hepatoma cell lines. 5, 6 However, it has become more apparent that during carcinogenesis, tumor cells tend to downregulate the growth-inhibitory responses associated with TGF-β, and, instead, respond preferentially to the growth-promoting cues elicited by TGF-β signaling. 3, 7, 8 Moreover, inhibition of TGF-β signaling has been shown to suppress HCC growth, vascular invasion and neoangiogenesis by regulating critical factors involved in these processes. [9] [10] [11] Increased serum levels of TGF-β1 are associated with poor prognosis of HCC patients and application of TGF-β inhibitors showed antitumor activity and improved clinical outcome; 12, 13 these findings suggest that a subset of human HCC tumors rely on TGF-β signaling for progression. Nevertheless, the underlying mechanisms responsible for hyperactivation of oncogenic TGF-β signaling in HCC are poorly understood.
Krüppel-like factor 4 (KLF4) is a zinc-finger transcription factor that is expressed in terminally differentiated epithelial cells and has diverse functions in cell differentiation, proliferation, embryogenesis and pluripotency. 14 Recent studies demonstrated that KLF4 transcriptionally upregulates TGF-β1 and contributes to cardiac myofibroblast differentiation. 15 Conversely, KLF4 can inhibit TGF-β1/Smad3 function by competing with Smad3 for the C terminus of the co-activator p300/CBP. As such, KLF4 promotes inflammatory responses in macrophages, 16 suggesting that KLF4 interacts with TGF-β pathway under non-cancerous conditions as well. Research conducted over the past decade has highlighted the significance of KLF4 deregulation in cancer development and progression. 17 However, little is known about the impact of deregulated KLF4 on TGF-β signaling in the context of tumor development. We and others have recently characterized KLF4 as a potent tumor suppressor in HCC, demonstrating that loss of KLF4 promotes tumorigenesis and epithelial-tomesenchymal transition of HCC cells. 18 Because active TGF-β signaling is a key inducer of epithelial-to-mesenchymal transition in HCC, we hypothesized that decreased KLF4 expression contributes to hyperactivation of TGF-β signaling and subsequent epithelial-to-mesenchymal transition and HCC progression.
In this study, we have evaluated the potential inhibitory effect of KLF4 in regulating TGF-β/Smad signaling in human HCC tissue and cell lines. We show that KLF4 blocks TGF-β signal transduction by transcriptionally activating Smad7; deletion of the zinc-finger domain (ZFD) of KLF4 abrogated this effect. Taken together, our study demonstrates that loss of KLF4 transcriptionally downregulates Smad7 in human HCC. This, in turn, increases TGF-β signaling and tumor progression of HCC.
RESULTS
Expression of KLF4, p-Smad2, p-Smad3 and Smad7, and their correlation with prognostic significance in HCC patients Using a tissue microarray (TMA), we first investigated the expression of KLF4 and related TGF-β signaling molecules in 148 pairs of primary HCC and matched adjacent non-tumor tissue obtained from patients who underwent liver resection. We found that reduced KLF4 expression was accompanied by decreased Smad7 expression but increased expression of p-Smad2 and p-Smad3 in primary HCC tissues when compared with those in the matched non-tumor tissues (Figures 1a and b; Supplementary  Table S2 and S3). These results were verified by western blot analysis ( Figure 1c ). Moreover, KLF4 positively correlated with Smad7, and negatively with p-Smad2 and p-Smad3 in primary HCC specimens (Figures 1d and e ). Smad7 expression in HCC inversely correlated with p-Smad2 and p-Smad3 expression ( Figure 1d , Supplementary Figure S1 ). In addition, decreased expression of KLF4 and Smad7 was associated with malignant cilinicopathological features of HCC, including younger age, higher AFP level, larger tumor size, macrovascular invasion and advanced tumor stage ( Supplementary Table S4 and S5). Univariate survival analysis demonstrated that reduced KLF4 and Smad7 expression and increased p-Smad2 and p-Smad3 levels in primary HCCs were significantly associated with reduced overall survival and relapse-free survival after surgery (Supplementary Figure S2 ; Supplementary Table S6 ). Multivariate analysis further revealed that, along with well-established prognostic factors, such as macrovascular invasion, reduced expression of KLF4 was an independent prognostic factor for unfavorable clinical outcome of HCC patients ( Supplementary Table S6 ).
Activation of TGF-β/Smad signaling promotes migration and invasion of human HCC cells
We investigated the integrity of TGF-β/Smad signaling and the response of this pathway to TGF-β1 in human HCC cell lines. As shown in Figure 2a , all components of the TGF-β signaling pathway were detected in most of the HCC cell lines used in this study. The only exceptions were loss of TGF-β type II receptor in SNU475 cells and deficiency of Smad3 in SNU398 cells. Because phosphorylation of receptor-activated Smads at two serines in their C-terminal SXS motif is a crucial step in TGF-β signal transduction, the activity of TGF-β in HCC cells was measured by immunoblot using specific p-Smad2 (Ser465/467) and p-Smad3 (Ser423/425) antibodies in the presence or absence of TGF-β1. HCC cells showed very low levels of basal p-Smad2 and p-Smad3 expression. In contrast, TGF-β1 stimulation of most HCC cell lines resulted in upregulation of p-Smad2 and/or p-Smad3 (Figure 2b ; Supplementary Figure S3 ). These data indicate that the TGF-β signaling pathway is intact and functional in most of HCC cell lines.
We next determined the effect of TGF-β signaling on the biological behaviors of HCC cells. As shown in Figures 2c and d , stimulation of SNU387 and SNU423 cells with TGF-β1 (3 ng/ml) promotes cell migration and invasion, whereas inhibition of TGF-β signaling by SB-431542 (0.3 μM), a potent and specific inhibitor of TGF-β type I receptor kinases, completely abrogated this effect. Nevertheless, cell proliferation was not affected by TGF-β1 or TGF-β1+SB-431542 treatment (Figure 2e ).
KLF4 overexpression attenuates TGF-β signal transduction upon TGF-β1 stimulation in HCC cells
Given that nuclear accumulation of Smad2/Smad3 is a key feature of TGF-β signal activation, we tested whether KLF4 overexpression affects the nuclear localization of Smad2/Smad3 in HCC cells. By performing immunofluorescent staining in SNU387 cells, we found that TGF-β1 treatment significantly increased the nuclear translocation of Smad2/Smad3. In contrast, KLF4 overexpression significantly suppressed nuclear translocation of Smad2/Smad3 upon exposure to TGF-β1 ( Figure 3a ). To determine whether the transcriptional activity of KLF4 is involved in this process, we constructed a KLF4 vector (KLF4ΔZFD) lacking the ZFD (Supplementary Figure S4A ). Similar to full-length KLF4, KLF4ΔZFD protein was mainly distributed in the nucleus (Supplementary Figure S4B ). However, in contrast to the full-length protein, KLF4ΔZFD lost both its transcriptional activity (Supplementary Figure S4C ) and its inhibitory effect on Smad2/Smad3 nuclear translocation upon TGF-β1 stimulation (Figure 3 ). To confirm these findings, cytoplasmic and nuclear protein extracts from SNU387 cells were subject to western blot analysis. As shown in (c) SNU387 and SNU423 cells were cultured with or without TGF-β1 (3 ng/ml), or with TGF-β1 (3 ng/ml)+SB-431542 (0.3 μM) as indicated, and cell migration was assessed by scratch assay. Shown are photos taken at the indicated time points after the cultures were wounded by scratching. Quantification of cell migration is shown on the right measured by ImageJ2x software, *Po0.05; data are expressed as mean ± s.e.m. of three independent experiments. (d) SNU387 and SNU423 cells were treated as described above and subjected to cell invasion assay. Representative photos are shown (left panels). Control cell groups (Ctrl) were given an arbitrary invasion percentage of 100% (right panels); data are expressed as mean ± s.e.m. of three independent experiments, *Po0.05. (e) SNU387 and SNU423 cells were treated as described above and subjected to cell proliferation assay; data are expressed as mean ± s.e.m of three independent experiments.
Supplementary Figure S5 , KLF4 overexpression inhibited nuclear localization of total and phosphorylated Smad2, Smad3 and the Co-Smad Smad4 in the presence of TGF-β1, whereas deletion of its ZFD abrogated this effect. These findings suggest that KLF4 inhibits nuclear localization of Smad2/Smad3 in HCC cells upon TGF-β1 stimulation via its transcriptional activity.
Because phosphorylated Smad2/Smad3 mainly localized in the nucleus, we hypothesized that KLF4 suppresses nuclear retention of Smad2/3 through inhibiting their phosphorylation. As shown in Figure 4a , KLF4 overexpression in SNU387 and SNU423 cells, which showed low levels of basal KLF4 expression (Supplementary Figure S6A ), significantly inhibited phosphorylation of Smad2/ Smad3 and expression of plasminogen activator inhibitor type 1, a prototypic TGF-β target gene, upon exposure to TGF-β1. However, KLF4 overexpression did not change the expression levels of total Smad2/Smad3 or Smad4. Moreover, deletion of the KLF4 ZFD significantly abrogated the inhibitory effect of KLF4 on Smad2/ Smad3 phosphorylation and plasminogen activator inhibitor Figure S6B ). These results suggested that KLF4 suppresses phosphorylation of Smad2/Smad3 via its transcriptional activity in the HCC cells.
As phosphorylated Smad2 and Smad3 are major mediators of TGF-β signaling, we further tested the role of KLF4 in Smad2/Smad3-mediated transcriptional activity. As shown in Figure 4c , overexpression of KLF4 in SNU387 and SNU423 cells resulted in a marked decrease in the activity of pSBE4-Luc, a Smad3-specific luciferase reporter, and pARE-Luc, a Smad2specific luciferase reporter, following treatment with TGF-β1. Nevertheless, deletion of the ZFD of KLF4 significantly abrogated KLF4 Loss Exacerbate TGF-β Signaling in HCC its negative impact on the activity of both SBE4-Luc and ARE-Luc upon TGF-β1 stimulation.
Because TGF-β signaling promotes metastatic potential of HCC cells, we determined whether KLF4 inhibits TGF-β-induced migration or invasion of HCC cells. As demonstrated in Figures 4d and e, KLF4 inhibits migration and invasion of SNU387 cells, and this inhibitory effect was much more significant upon TGF-β1 stimulation. Furthermore, TGF-β-mediated cell migration was not substantially altered in the cells lacking Smad7 when KLF4 was overexpressed (Supplementary Figure S6C) .
KLF4 inhibits TGF-β signaling via activation of Smad7 transcription Because KLF4 has been reported to interact with Smad3 in myofibroblasts, 19 we examined whether KLF4 interacts with Smad2 and/or Smad3 in HCC cells and whether this interaction could influence the phosphorylation status of Smad2/Smad3. We found that KLF4 interacts with both Smad2 and Smad3 independent of its ZFD (Supplementary Figure S7) . As such, the interaction between KLF4 and Smad2/Smad3 may not correlate with phosphorylation of Smad2/Smad3. Given that the suppressive function of KLF4 on TGF-β signaling depends on its ZFD, we investigated whether KLF4 regulates the key components of TGF-β signaling, including Smad7, at a transcriptional level. As shown in Figure 5 , enforced KLF4 expression in SNU387 and SNU423 cells increased levels Smad7 mRNA and protein in a dosedependent manner, whereas deletion of its ZFD eliminated this effect. In contrast, but consistent with these data, KLF4 knockdown in PLC/PRF/5 cells using siRNA led to a dose-dependent decrease in the expression of Smad7 mRNA and protein ( Figure 5 ). Altered KLF4 expression in these HCC cells had no impact on the expression levels of TGF-β type II receptor, TβRI, Smad2, Smad3, Smad4, Smad6, Smurf1 or Smurf2 ( Figure 5 ). These results suggest that KLF4 specifically regulates Smad7 expression at the transcriptional level.
To further characterize the regulatory role of KLF4 on Smad7 expression, we analyzed the Smad7 promoter sequence for the presence of potential KLF4-binding sites using the KLF4 consensus sequence 5′-G/AG/AGGC/TGC/T-3′. 20 We identified three putative KLF4-binding elements (referred to as sites #1, #2 and #3) in the Smad7 promoter region and constructed several mutant reporter constructs: pS7Pro+40 (lacks all binding sites), pS7Pro+14 (contains binding site #1), pS7Pro-56 (contains sites #1 and #2) and pS7Pro-127 (contains sites #1, #2, and #3) ( Figure 6a ). We then co-transfected the deletion mutant reporters with KLF4, KLFΔZFD or control pcDNA3.1 into SNU387 cells; pGL3-basic and pFLAG-KLF4 were co-transfected as negative controls. Overexpression of wild-type KLF4 but not KLF4ΔZFD enhanced the promoter activity of pS7Pro-56 and pS7Pro-127. In contrast, overexpression of either KLF4 or KLF4ΔZFD had no impact on the promoter activity of pS7Pro+40 and pS7Pro+14 (Figure 6b ). Moreover, mutations of the conserved nucleotides in the KLF4-binding site #2 (pS7Pro-127Mut) significantly decreased the promoter activity of pS7Pro-127 (Figures 6a and c) . These findings indicate that KLF4binding site #2 is essential for the transcriptional regulation of Smad7 by KLF4. To provide direct proof that KLF4 is recruited to the endogenous Smad7 promoter during transcription in vivo, we performed chromatin immunoprecipitation assays using chromatin prepared from SNU387, SNU423 and PLC/PRF/5 cells and a primer set flanking the 302-bp (−117 to +185) region of the Smad7 promoter. The 302-bp DNA fragment was amplified from the precipitates by anti-KLF4 antibody but not by control immunoglobulin G (Figure 6d ). Collectively, these results clearly suggested that KLF4 positively regulates Smad7 transcription via direct binding to the KLF4-binding site #2.
We next examined whether upregulation of Smad7 by KLF4 is sufficient to inhibit TGF-β signaling. As shown in Figure 6e , KLF4 overexpression upregulated Smad7 expression and suppressed Smad2/Smad3 phosphorylation and plasminogen activator inhibitor type 1 expression in HCC cells when treated with TGF-β1. In contrast, Smad7 knockdown using siRNA rescued Smad2/Smad3 phosphorylation and plasminogen activator inhibitor type 1 expression upon TGF-β1 stimulation.
DISCUSSION
In this report, we provided many lines of evidence that KLF4 in human HCC transcriptionally activates Smad7 expression, whereas loss of KLF4 leads to downregulation of Smad7 and thereby hyperactivation of oncogenic TGF-β signaling and subsequent tumor progression ( Figure 7) . First, the expression levels of KLF4, p-Smad2, p-Smad3 and Smad7 correlate with prognostic significance in HCC patients. Second, activation of TGF-β/Smad signaling promotes migration and invasion of human HCC cells, and KLF4 inhibits those effects. Third, KLF4 overexpression attenuates TGF-β signal transduction upon TGF-β1 stimulation in HCC cells. Finally, KLF4 inhibits TGF-β signaling via activation of Smad7 transcription. Our clinical and mechanistic studies strongly suggest the important role of this KLF4-Smad7-TGF-β signaling axis in HCC development and progression and a potential target for designing effective therapy against this deadly disease.
Elevated serum levels of TGF-β1 in patients with HCC correlate with worse prognosis, suggesting that hyperactive TGF-β signaling may represent a hallmark of this tumor type. 12 In this study, we detected increased phosphorylation of Smad2/3 in primary HCC compared with adjacent non-tumorigenic tissue. This provided us with the first direct evidence for activation of TGF-β signaling in human HCC cells in vivo. Our data also revealed significant correlation between increased expression of phosphorylated Figure 4 . Influence of KLF4 expression on phosphorylation of Smad2/Smad3, Smad2/Smad3-mediated transcriptional activity and biological behavior of HCC cells. (a) SNU387 and SNU423 cells were transfected with pcDNA3.1 (Ctrl) or vector pFLAG-KLF4 (pKLF4) as indicated. Fortyeight hours after transfection, cells were treated with or without TGF-β1 (3 ng/ml) as indicated and total protein lysates were prepared for western blot analysis. (b) SNU387 and SNU423 cells were transfected with pcDNA3.1 (Ctrl) or vector pFLAG-KLF4ΔZFD (pKLF4ΔZFD) as indicated. Cells were treated and subjected to western blot analysis as described in a. (c) The Smad3-specific luciferase reporter pSBE4-Luc (left panel) or Smad2-specific luciferase reporter pARE-Luc (right panel) was transfected in triplicate with pFLAG-KLF4, pFLAG-KLF4ΔZFD or control vector pcDNA3.1 into SNU387 and SNU423 cells. Forty-eight hours after transfection, cells were treated with or without TGF-β1 (3 ng/ml) for 24 h, the activity of the promoter reporters was measured and expressed as the fold activity in their respective control groups without TGF-β1 treatment; data are expressed as mean ± s.e.m. of three independent experiments. (d) SNU387 cells were transfected with pcDNA3.1 (Ctrl), pFLAG-KLF4 (pKLF4) or pFLAG-KLF4ΔZFD (pKLF4ΔZFD) as indicated. Forty-eight hours after transfection, cells were cultured with or without TGF-β1 (3 ng/ml), and cell migration was assessed by scratch assay. Shown are photos taken at the indicated time points after the cultures were wounded by scratching (left panels). Quantification of cell migration is shown below measured by ImageJ2x software; data are expressed as mean ± s.e.m. of three independent experiments, *P o0.05. (e) SNU387 cells were treated as described above and subjected to cell invasion assay. Representative photos are shown (right panels). Quantification of cell invasion is shown below, control cell group without TGF-β1 treatment was given an arbitrary invasion percentage of 100% (right panel); data are expressed as mean ± s.e.m of three independent experiments, *P o0.05.
Smad2/3 and both reduced patient survival and enhanced metastatic potential of HCC cells when exposed to TGF-β1 in vitro, indicating a pro-metastatic role of TGF-β/Smad signaling in HCC. Previous work has described dual roles for TGF-β signaling -as a tumor suppressor in premalignant lesions and early HCC and as a cancer promoter in developed hepatoma. 3 Functional switching of this pathway in human gastrointestinal cancers, such as colorectal and pancreatic cancers, commonly involves deletion or mutation of the TGF-β signal components. 21, 22 However, alterations in these genes are rare in HCC. Consistent with earlier were transfected in triplicate with pFLAG-KLF4, pFLAG-KLF4ΔZFD or the control vector pcDNA3.1 into SNU387 cells. Co-transfection of pFLAG-KLF4 and pGL3-basic was used as a negative control. The activity of the promoter reporters was measured 36 h after transfection, and the activities in the negative control and treated groups were expressed as the fold activity in their respective control groups; data are expressed as mean ± s.e.m. of three independent experiments. (c) The Smad7 promoter reporters (pS7Pro-127/ − 127Mut/+40) were transfected in triplicate as described in b. Co-transfection of pFLAG-KLF4 and pGL3-basic was used as a negative control. The promoter activity was measured and expressed as described in b. (d) Chromatin was extracted from SNU387, SNU423 and PLC/PRF/5 cells. ChIP assays were performed using a specific anti-KLF4 antibody or IgG as a negative control and oligonucleotides flanking the Smad7 promoter regions containing putative KLF4-binding sites. Chromatin fragments without IgG or the antibody were used as input controls. (e) SNU387 cells were transfected with 4 μg pcDNA3.1 vector plus 50 nM control siRNA (pcDNA3.1+siCtrl), 4 μg pFLAG-KLF4 vector plus 50 nM control siRNA (pKLF4 +siCtrl), 4 μg pFLAG-KLF4 vector plus 50 nM Smad7 siRNA (pKLF4+siSmad7) in six-well plates. Forty-eight hours after transfection, cells were treated with or without TGF-β1 (3 ng/ml) for 3 h as indicated and total protein lysates were prepared for western blot analysis.
reports, we observed intact and functional TGF-β signaling in most of the investigated HCC cell lines. 23 Therefore, in these cell lines, it is likely that the oncogenic shift of TGF-β signaling may be determined by some other factors, for example, CD44 overexpression 24 or p53 loss. 25 Loss of KLF4 likely contributes to the enhanced invasive and metastatic phenotypes of tumors. 14, 26, 27 Here, we report that KLF4 is a potent tumor suppressor in HCC. We also show that loss of KLF4 transcriptionally downregulates Smad7 expression in HCC, which leads to hyperactivation of TGF-β signaling and subsequent tumor progression. Mechanistically, this effect is not attributed to the protein-protein interaction between KLF4 and Smad2/3. Instead, it is dependent on the DNA-binding activity of KLF4, as deletion of KLF4 ZFD completely abrogated its inhibitory effect on TGF-β signal transduction. Previous studies have shown that KLF4 suppresses TGF-β1 signaling, thereby promoting an inflammatory response in macrophages; KLF4 functions in this manner by competing with Smad3 for the co-activator p300/CBP, independent of its DNA-binding activity. 16 To the best of our knowledge, this is the first study to explore the impact and mechanism of KLF4 on TGF-β signaling in the context of cancer. The present study not only expands our knowledge of KLF4's function as a tumor suppressor, but also provides an experimental rationale for designing novel and tumor specific therapy for HCC.
Smad7 is a well-established key negative regulator of TGF-β signaling and an important cross-talk mediator between the TGF-β/Smad pathway and other signaling networks. 28 Previous work has indicated that Smad7 may exert pro-or anti-tumorigenic effects depending on the given tumor type. 29 In human HCC, the expression profile of Smad7 remains controversial. Park et al. 30 reported a much higher Smad7 expression rate in advanced tumors than in dysplastic nodules and early HCCs. In contrast, Xia et al. 31 identified decreased expression of Smad7 in HCC samples, particularly in patients with early recurrence and poor prognosis. Our data demonstrated reduced Smad7 expression in HCC compared with matched non-tumorigenic tissue, which was associated with malignant clinicopathological features of HCC and unfavorable clinical outcome of patients after surgery. Using a mouse model of HCC induced by diethylnitrosamine, Wang et al. 32 showed that Smad7 knockout mice displayed higher tumor incidence and multiplicity than wild-type mice. In addition, tumor cells from Smad7 knockout mice demonstrated increased proliferation, diminished apoptosis and higher colony formation compared with those from wild-type littermates. 32 These findings support the notion that Smad7 is a critical tumor suppressor in HCC. As such, in the present study, we have focused on how KLF4 directly regulates transcription of the Smad7 gene. To avoid possible interference from other transcription factors, for example, Smad2/3, Sp1, we cloned a very short proximal region of the Smad7 promoter (ranging from − 127 bp to +287 bp), which included three putative KLF4-binding sites. This region has not been well studied because of significant change of the initiation site in comparison with a previous report; 33 the physiologic role of this region in the regulation of Smad7 expression remains to be defined. Our study provides novel insight into the functional role of the proximal region of the Smad7 promoter in the regulation of Smad7 gene expression. Nevertheless, KLF4 may activate Smad7 expression at the transcriptional level independent of TGF-β/ Smads signaling and Smad7 may execute its multiple functions though various mechanisms. Future studies are clearly warranted to dissect in great details the molecular basis underlying the transcriptional activation of Smad7 expression by KLF4 and the detailed mechanisms that Smad7 inhibits receptor-activated Smads phosphorylation in HCC.
In summary, our data show that loss of KLF4 in human HCC transcriptionally downregulates Smad7 expression, thereby leading to hyperactivation of oncogenic TGF-β signaling and subsequent tumor progression. The present study not only KLF4 Loss Exacerbate TGF-β Signaling in HCC expands our current knowledge on the tumor suppressive role of KLF4 in HCC, but also provides novel insight into the mechanism of TGF-β signaling in human HCC. Our results strongly suggest a routine evaluation of KLF4 by immunohistochemistry in primary HCC after surgical resection, which may offer a novel pathological biomarker for forecasting patient prognosis and improve our insight into patient selection for TGF-β-targeted therapy.
MATERIALS AND METHODS
The Supplementary Methods section contains details about the materials and methods regarding immunohistochemistry and TMA analysis, 26, 34 Western blot analysis, 26 cell proliferation assay, 26, 27 scratch assay, 26 cell invasion assay, 26 RNA extraction and reverse-transcriptase PCR analysis ( Supplementary Table S1 ), immunofluorescent cell staining, construction of mutant KLF4 with deletion of zinc-finger domain (KLF4ΔZFD)-expressing vectors, construction of Smad7 promoter reporter plasmids and mutagenesis, and chromatin immunoprecipitation assay. 27 Patients, clinicopathological analysis and tissue specimens Patient information and extraction of follow-up and clinicopathological data were previously described. 34 Matched pairs of HCC and formalinfixed, paraffin-embedded non-tumor tissue blocks for TMA and paired fresh HCC and non-tumor tissue specimens were collected as previously described. 34 The study protocol was approved by the Shanghai Jiaotong University Institutional Review Board, and informed written consent for use of the tissue specimens was obtained from each patient or his or her guardian.
TMA construction and immunohistochemistry TMA construction was previously described in detail. 34 Standard immunohistochemical procedures were performed with human HCC TMA specimens using anti-KLF4 (1:500, Santa Cruz Biotechnology, Santa Cruz, CA, USA), antip-Smad2 (Ser465/467) (1:2000, AB3849, Millipore, Princeton, NJ, USA), p-Smad3 (Ser423/425) (1:50, ab51451, Abcam, Cambridge, MA, USA) and Smad7 (1:50 dilution, MAB2029; R&D Systems, Minneapolis, MN, USA) antibodies. The staining results were scored by two pathologists blinded to the clinical data as described previously 26, 34 and in Supplementary Methods. Use of archived tissue specimens was approved by the Shanghai Jiaotong University Institutional Review Board.
Statistical analysis
Statistical analyses were performed using the SPSS software program (version 17.0; IBM Corporation, Armonk, NY, USA). For continuous variables, data were expressed as medians in the interquartile range and compared using the Kruskal-Wallis test. For categorical variables, data were expressed as numeral counts and percentages and compared using the Pearson χ 2 -test or Fisher's exact test. Differences in protein expression between the matched specimens were examined using the marginal homogeneity test or Mann-Whitney U-test. Survival rates were calculated and survival curves were plotted using the Kaplan-Meier method, and differences were compared using the log-rank test. Univariate Cox regression was used to analyze differences in survival among patient groups. The significant factors in the univariate analyses were included in multivariate Cox proportional hazards models. The significance of the in vitro data in the groups was determined using a two-tailed Student's t-test. Statistical significance was indicated by a conventional P-valueo0.05. 35, 36 ABBREVIATIONS ChIP, chromatin immunoprecipitation; FFPE, formalin-fixed paraffinembedded; KLF4, Krüppel-like factor 4; EMT, epithelial-to-mesenchymal transition; ZDF, zinc-finger domain; PBS, phosphate-buffered saline; PBS-T, PBS containing 0.1% Triton X-100; PCR, polymerase chain reaction; qPCR, quantitative PCR; RT, reverse transcription; siRNA, small interfering RNA; TGF, transforming growth factor; TMA, tissue microarray; UTR, untranslated region.
